Loading...
In February 2009, the FDA announced that manufacturers of metoclopramide must add a boxed warning (black box) on drug labels to warn providers and patients about the risk for tardive dyskinesia (TD) with chronic or high-dose use. Metoclopramide increases the rate of stomach emptying and is used as short-term treatment (<3 months) for gastroesophageal reflux and gastroparesis in patients who do not respond to other treatments. The director of the FDA’s Center for Drug Evaluation and Research commented that although the FDA wants patients and health professionals to be able to make informed decisions regarding treatment, chronic use of metoclopramide should be avoided, except in rare circumstances in which benefit outweighs risk.
TD is charact…